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Abstract
Introduction: Simultaneous use of contraceptive hormones and anti-retroviral therapy (ART) may theoretically lessen the
effectiveness of both.Women on ARTneed assurance that hormonal contraception is safe and effective.The sub-dermal implant
is an ideal product to study: low and steady progestin release and no adherence uncertainties. We sought to determine if the
medications’ effectiveness is compromised.
Methods: We conducted a prospective cohort study among women on first line ART (stavudine or zidovudine and
lamivudinenevirapine). We recruited new implant users and matched them to women not using hormonal contraception,
based on age and baseline CD4. Participants were followed prospectively for up to two years, recording serial CD4 measures and
medical histories.We used generalized growth curve models and Wald chi-square tests to compare changes in CD4 counts across
study groups. Prospective CD4 measures were censored (excluded) if any of the following events occurred: change in ART,
implant removal or use of any hormonal contraception among controls. We examined incidence of opportunistic infection and
pregnancy.
Results: We matched 48 implant users to 33 non-hormonal controls. Over time, CD4 counts for both groups rose slightly but
did not deviate significantly from each other (p0.44). Opportunistic infection rates did not differ between the groups. None of
the implant users and one of the non-hormonal controls became pregnant during follow-up.
Conclusions: This small study found concurrent use of contraceptive implants and ART to be safe and effective. Although
other hormonal contraceptive products and ART regimens may interact in unknown ways, the results of this study are
reassuring.
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Introduction
Women living with HIV using combination anti-retroviral
therapy (ART) need safe and effective contraceptive options
to avoid unintended pregnancy. Hormonal contraceptives,
including orals and injectables (such as depot medroxypro-
gesterone acetate, DMPA), are the most widely used type
of modern method in sub-Saharan Africa (approximately
15 million current users in the region) [1]. ART is used by
approximately three million women there [2].
One concern about hormonal contraception is that it may
accelerate HIV-related disease progression by interfering with
the body’s natural immune responses. Seminal research
examining viral set points, changes in CD4 counts and
mortality has raised concerns [35], but systematic reviews
find no strong associations between hormonal contraception
and disease progression [68]. A second concern involves
concomitant use of ARTand hormonal contraception, and the
potential for interactions and compromised effectiveness of
each [9].
Valid measurement of correct and consistent use of
hormonal contraception is difficult for products that require
on-going user adherence; thus, contraceptive method failure
(pregnancy) in the presence of ARTuse can be misinterpreted.
But sub-dermal implants are inserted and removed by
clinicians; this circumvents adherence problems and provides
more certainty about actual use.We conducted a prospective
cohort study in Kenya to examine how concurrent use of
hormonal contraceptive implants and ART might lessen the
effectiveness of both medications.
Methods
The study was reviewed and approved by two Institutional
Review Boards at FHI 360 in North Carolina, USA, and the
Kenya Medical Research Institute, Nairobi, Kenya. Women
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1voluntarily enrolled through a written informed consent
process. All participants were receiving standard HIV-related
care at the comprehensive care centre of Kenyatta National
Hospital.
We recruited 60 women on ART who wanted to use a
levonorgestrel (LNG) contraceptive implant (the product is
marketed as Jadelle†). The following additional inclusion
criteria were applied: aged between 18 and 44 years, last CD4
count of at least 200 cells, at least six months on a first
line therapy of stavudine or zidovudine plus lamivudine
nevirapine, sexually active and willing to continue ART. (We
chose first line therapies to maximize participation, though
other ART regimens could be studied, since contraindications
to implant use are non-existent.). We applied the following
exclusion criteria to allow enough of a wash-out period for
previous hormonal contraception: 5five months since last
DMPA injection, 5two months since last dose of oral con-
traceptives, 5two months since removal of an LNG intrau-
terine device and 5two months since removal of contra-
ceptive implant. We excluded women who were not appro-
priate candidates for an implant: currently pregnant, desire
for pregnancy in the next 12 months, surgically sterilized
(including partner vasectomy) and medical contraindications
for implant use. To avoid unstable health histories that might
require other interventions, we excluded women who were
pregnant within the past six months, women currently taking
rifampicin and women in unstable WHO stage 3 or 4 HIV
disease.On the dayofenrolment, a new blood drawwasdone
and sent to the lab for analysis and the sub-dermal implant
was inserted. Once the new CD4 count was available and
confirmed to be at least 200 cells, we added the implant user
to a list of women needing a matched control and recorded
participant ID number, current age and CD4 count.
We recruited a cohort of matched controls who were not
using hormonal contraception. We applied three matching
criteria: using the same ART regimen as cases; current age
(95 years); and CD4 count (950 cells). We accepted
baseline CD4 counts up to six months old as long as the
participant had not used hormonal contraception for the
wash-out periods (as specified above) before the blood
specimen was collected. Furthermore, the baseline CD4
count was only usable if the participant had been on ART
for at least six months prior to that specimen being collected
and if it was at least 200 cells. In addition to the criteria
outlined above, we applied the following exclusion criteria
for controls to better avoid possible contamination: any use
of hormonal contraception between baseline CD4 and
enrolment date; plans to use hormonal contraception in
the next 12 months.
Regular hospital services included periodic check-ups, ART
provision and periodic blood draws to measure CD4 counts.
We did not interfere with clinical management of patients
but did advocate for blood draws and lab tests to maintain
the routine standard of care at that facility (every six months,
if stable).
We aimed to recruit 60 implant users and an equal number
of matched controls, based on variance of change in CD4
counts from previous research in Uganda and Zimbabwe [10]
and the following assumptions: the mean change from
baseline CD4 will not differ by more than 100 cells per mL
compared with the non-hormonal group, two-sided 0.05
level test, 80% power to detect a difference of 105 cells per
mL in the change from baseline and 15% lost to follow-up or
death.
We followed the participants prospectively and recorded
CD4 counts as they became available through the regular
services (approximately every six months). In addition, each
time participants returned for regular services, they were
asked to visit the study nurse and provide an update on
contraceptive use, illnesses and pregnancy. At that time, the
study nurse also reviewed medical records, if feasible. At the
close of the study, final interviews and medical record reviews
were conducted. The following key information was tran-
scribed to study forms: ART medications/dates, CD4 counts/
dates, opportunistic infections/dates and pregnancies/dates.
Table 1. Characteristics of matched levonorgestrel implant
users and non-hormonal controls
Characteristics
Implant user
N48
Non-hormonal
control* N33
Mean age (s.d.) 32.0 (5.3) 33.6 (5.4)
Mean baseline CD4 (s.d.) 420 (121) 417 (140)
Education (%)
Less than primary 16.7 15.2
Completed primary 33.3 30.3
Completed secondary or higher 50.0 54.5
Marital status (%)
Single 41.7 36.4
Married 58.3 63.6
Number of children (%)
01 33.3 42.4
2 37.5 48.5
3 29.2 9.1
Years on ART (s.d.) 2.84 (0.99) 2.97 (1.04)
Censoring events within
12 months (%)
Implant removal 12.5 
Change in ART 31.3 15.2
Adoption of hormonal
contraception
 3.0
Number of usable**
CD4 measures (%)
baseline only 22.9 0.0
1 16.7 15.2
2 47.9 60.6
3 6.3 15.2
4 6.3 9.1
Usable** CD4 counts (%),
12 months or later
47.1 72.7
*32 were using condoms and 1 participant was not using
contraception.
**Excludes CD4 measures taken after switching ART, implant removal
or use of hormonal contraception among controls.
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2The primary outcome was change in CD4 count over time,
comparing implant users to their non-hormonal controls.
Secondary outcomes included the incidence of pregnancy
and opportunistic infections. We used generalized growth
curve models and Wald chi-square tests to compare changes
in CD4 counts across the study groups, which controls for
time in study. Prospective CD4 measures were censored
(excluded), if any of the following events occurred: change in
ART, implant removal and use of hormonal contraception
among controls. Analyses were conducted using SAS 9.2 (SAS
Institute, Cary, NC, USA).
Results
We successfully recruited 60 implant users, but six were later
deemed ineligible for the following reasons: baseline CD4
count below 200 cells (two), missing baseline CD4 count
(one) and incorrect ART (three were using tenofovir dis-
oproxil fumarate (TDF) regimens). Recruitment of matched
controls was more difficult. A total of 36 women were
recruited, but three participants were later deemed ineligible
for the following reasons: incorrect ART regimen, use of
hormonal contraception in wash-out period and matching
error. Of the 33 eligible, non-hormonal controls, 15 were
matched to an additional implant user. Thus, we analyzed
data on 33 non-hormonal controls and 48 implant users for a
total study size of 81 women.
Because of matching, implant users and non-hormonal
controls were similar in terms of age and baseline CD4 counts
(Table 1). In addition, the groups were similar in terms of
education, marital status and number of years on ART.
Implant users had higher parity levels than non-hormonal
controls. During follow-up, 44% of implant users experienced
censoring events (implant removal or change in ARTregimen)
that made subsequent CD4 measures unusable. In contrast,
18% of non-hormonal controls had censoring events, and so
the distribution of number of usable CD4 measures in the
two groups differed. Nearly three-quarters of non-hormonal
controls had a usable 12-month measure compared to about
half of implant users.
Over time, the trend in CD4 counts was similar for implant
users and non-hormonal controls (Figure 1), with slight
increases in CD4 counts in both groups. On average, there
was an 86 cell per mL difference between the two groups
(p-value0.44), after controlling for participant duration in
the study. The mean increase in CD4 was 59 for implant
users and 101 for non-hormonal controls at 12 months
(p-value0.10). No participants died during follow-up. Six
participants in the complete cohort (n96) were diagnosed
with opportunistic infection (two implant users and four
non-hormonal control participants). The two implant users
acquired oral candidiasis and herpes zoster, while infections
among the non-hormonal controls included pneumonia
(three) and cryptococcal meningitis (data not shown). None
of the implant users and one of the non-hormonal controls
became pregnant during follow-up. Of the 60 implant users
enrolled, six participants (10%) had the product removed
within 12 months of insertion.
Discussion
We found that use of a levonorgestrel sub-dermal implant
did not adversely affect patients on ART. CD4 counts rose
slowly and equally in women using implants and in non-
hormonal users. Few opportunistic infections occurred in
both groups. ART did not compromise contraceptive efficacy
of the implant. To our knowledge, this is the first attempt to
understand how simultaneous use of a levonorgestrel sub-
dermal contraceptive implant and ART may affect both HIV
progression and contraceptive effectiveness.
Many studies have examined the safety of hormonal
contraception among women living with HIV. Nearly all
showed that use of oral contraceptives or injectable DMPA
does not affect HIV progression [6]. A recent pharmacokinetic
Figure 1. Estimated trend of CD4 count by group (p-value=0.44).
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3study showed ART does not affect DMPA [11]. In terms of
slow-release contraceptive products, a small study by
Heikinheimo et al., found that the levonorgestrel intrauterine
device did not adversely affect women living with HIV or
increase genital shedding of HIV [12]. Recently, case reports
of contraceptive failure of an etonogestrel implant (while
using efavirenz) have raised concerns over simultaneous use
[13,14].
Our study has weaknesses, primarily related to the small
study size. Though we were hoping to have about twice the
number of participants, the recruitment and matching
requirements proved to be more difficult than anticipated.
Changing ART regimens also impacted our work and we had
to censor CD4 values that were affected. Regimen switching
was more common in the implant group (compared to the
non-hormonal group) due to timing of follow-up visits,
availability of medications and other administrative reasons,
not medical reasons. For control participants, we relied on
self-reports of ‘‘no hormonal use’’; unfortunately this is a
study weakness that has few solutions.
Our work is noteworthy for four reasons. First, we studied a
contraceptive product that releases progestin automatically
and with certainty; thus, we avoided reliance on self-reported
data (e.g. from oral contraceptive use if that product were
used in the study). Second, we matched women prospectively
on key factors, including ART regimen, baseline CD4 count
and age. Without this design feature, we would have risked
collecting data on extremely disparate cohorts and simulta-
neously introducing bias.Third, we carefully recorded changes
in ARTand contraception to verify exposures, correctly censor
data and preserve validity. Finally, our report is timely; for
example, WHO recently reviewed existing evidence and
concluded more research is needed on contraception and
HIV [15].
Conclusions
Sub-dermal implants are in the top tier of contraceptive
effectiveness [16] and their use is increasing in sub-Saharan
Africa [17]. In addition, millions of women in sub-Saharan
Africa are taking ART and access to medications is increasing
[18]. The results from this study provide some reassurance
that levonorgestrelsub-dermal implants aresafe and effective
contraceptive options for women living with HIV using ART. In
the broader context, increasing access to all family planning
methods will help prevent unintended pregnancy and thus
reduce HIV incidence from mother-to-child transmission [19].
Increasing access to sub-dermal implants through expansion
of both product procurement and provider training can have
tremendous public health impact.
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